Surety Medicine 
Patient undergoing eye examination - US Navy photo 

As with other critical programs, many Personnel Reliability Program personnel who staff selected chemical, biological and nuclear surety functions must meet vision conservation and readiness standards.         
                                                                                                                                                    -US Navy photo

October 2016 Surety Medicine Teleconference:

VISION CONSERVATION AND READINESS PROGRAM:  THE CMA PERSPECTIVE

Wednesday, 19 October 2016 will bring the next Surety Medicine Teleconference, at 1 pm (1300 hrs) Eastern Time.  The topic for September will be “Vision Conservation and Readiness Program:  The CMA Perspective.”  The presenter will be a civilian optometrist of the Department of Defense Tri-Service Vision Program. 

To receive access information for attending the presentation by dial-in audio or on your computer via Defense Collaboration Services (DCS), send an email request to:

usarmy.apg.medcom-aphc.mbx.surety-medicine@mail.mil

----------------------------------------------------------------------------------------------------------------

SCHEDULE OF SURETY MEDICINE TELECONFERENCES FOR FY 2017
 

DATE

                TOPIC    (Dates and topics subject to revision)

19 OCT 2016

Vision Conservation and Readiness Program: The CMA Perspective

16 NOV 2016

Building and Sustaining a PRP Clinical Quality Assurance Program

14 DEC 2016

The Ebola Epidemic: Lessons Learned on the Diagnosis, Evaluation
and Treatment of  Ebola Infections Relevant to the CMA

18 JAN 2017

Regulatory Policy Updates in Surety Medicine

15 FEB 2017

Respirator Clearance and PPE Assessments:  The Role of Use Testing

15 MAR 2017

Peripheral Vascular Disease, DVT, and Anticoagulation—
Assessing PRP Suitability

19 APR 2017

Abuse, Dependence and Substance Use Disorders: 
DSM-IV-TR vs. DSM-5

17 MAY 2017

Screening for Active TB or LTBI:  TB Skin tests vs. Alternatives

21 JUN 2017

Heat Stress Prevention and Management Issues
in the Surety Environment

19 JUL 2017

Syncopal Conditions:  Impacts on PRP Reliability

16 AUG 2017

Key Stakeholders in the ASAP -- Developing an Alliance
with the CMA

20 SEP 2017

Obstructive Sleep Apnea:  Screening, Diagnosis,
Treatment and Compliance: 
The PRP Perspective


ALERT:
  FDA Simplifies Rule for Anthrax PEP

FDA APPROVES ANTHRAX VACCINE FOR POST-EXPOSURE PROPHYLAXIS

The US Food and Drug Administration (FDA) has approved the current Anthrax Vaccine Adsorbed for use in combination with antibiotic therapy after a confirmed or suspected exposure to Bacillus anthracis, the causative agent for anthrax.  The vaccine had been approved in 1970 for pre-exposure protection of those who might be exposed to the organism, but this recent approval for use in post-exposure prophylaxis (PEP) approves the use of the vaccine in combination with selected antibiotics to significantly improve the chances of survival in patients exposed to inhaled anthrax, without the previously required use of an investigational new drug (IND) protocol.

Additional information is available from the FDA at: 

http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm474027.htm  


ALERT:  Autoinjector Shelf Life Extension Program:  Current Information

NERVE AGENT ANTIDOTE SHELF LIFE EXTENSION PROGRAM

The US Food and Drug Administration (FDA) is alerting health care professionals and emergency responders that specific lots of DuoDote combined nerve agent antidote auto-injectors have been approved for shelf life extensions beyond labelled expiration dates, some up to 31 October 2019.  Complete FDA information related to the auto-injector shelf life extension program can be found at:  http://www.fda.gov/Drugs/DrugSafety/ucm376367.htm .  

Information on this page also includes the latest updates (4/15/2016) on shelf life
extensions for the AtroPen (atropine), CANA (diazepam), morphine sulfate, and
pralidoxime chloride auto-injectors. 

_______________________________________________________________

SURETY MEDICINE REGULATIONS, GUIDANCE and USEFUL LINKS:         
(Common Access Card or Army Knowledge Online account required for access to some documents)

AR 50-1 Biological Surety: http://armypubs.army.mil/epubs/pdf/r50_1.pdf 

AR 50-5 Nuclear Surety: http://armypubs.army.mil/epubs/pdf/r50_5.pdf 

AR 50-6 Chemical Surety: http://armypubs.army.mil/epubs/pdf/r50_6.pdf 

AR 50-7 Army Reactor Program: http://armypubs.army.mil/epubs/pdf/r50_7.pdf 

DA PAM 50-5 Nuclear Accident or Incident Response and Assistance Operations: http://armypubs.army.mil/epubs/pdf/p50_5.pdf 

DA PAM 385-61 Toxic Chemical Agent Safety Standards:  http://armypubs.army.mil/epubs/pdf/p385_61.pdf

Army Directive 2013-03 (Chemical Accident or Incident Response and Assistance): http://www.apd.army.mil/pdffiles/ad2013_03.pdf

TB MED 507 Heat Stress Control and Heat Casualty Management: http://armypubs.army.mil/med/DR_pubs/dr_a/pdf/tbmed507.pdf

TB MED 590 Red Blood Cell Testing and Quality Assurance:
http://armypubs.army.mil/med/DR_pubs/dr_a/pdf/tbmed590.pdf

Medical Command (MEDCOM) Regulation 40-55 Guidance on Occupational Health Practices for the Evaluation and Control of Occupational Exposures to Biological Select Agents and Toxins: https://www.us.army.mil/suite/doc/22064586

Additional Guidance Document Sources:

Army Publishing Directorate:  http://armypubs.army.mil/index.html